TransMedics Group, Inc. Raises Revenue Guidance for the Full Year 2024
April 30, 2024 at 04:05 pm EDT
Share
TransMedics Group, Inc. raised revenue guidance for the full year 2024. For the period, the company expects revenue to be in the range of $390 million to $400 million, which represents 61% to 66% growth compared to the company's prior year revenue. Company's prior 2024 revenue guidance was $360 million to $370 million.
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
TRANSMEDICS GROUP, INC. 
